Weekender 10/7/16

Welcome to the newly designed BioLines Weekender. Our new format allows for easier reading on mobile devices. And, our user-friendly links allow you to easily register for BioNJ events, as well as add them to your Outlook calendar. To access full articles, please click on the article’s title.

The Weekender continues to feature the meaningful work being done by New Jersey’s vibrant life sciences community, such as TAXIS Pharmaceuticals‘ recent announcement that its lead clinical candidate, TXA709, received Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA) as well as Novartis‘ announcement that the FDA granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. (Many more exciting stories below!)

BioNJ continues to take pride in the work and commitment that our Members have made to developing therapies and cures for Patients while choosing to call New Jersey home.

This week biopharma leader Allergan released a study titled, “The Economic Impact of Allergan’s Operations in New Jersey,” which showed the operations of Allergan’s facilities in New Jersey currently generate an estimated economic impact of $732 million each year. This commitment is important for the State, its citizens and for society.

Congratulations to Adare Pharmaceuticals on the official opening of its Corporate Headquarters in Lawrenceville. We are propelled by this news as it’s so important to New Jersey’s economy to keep innovative biopharmaceutical companies in New Jersey.

We hope to see you at a future BioNJ event, including our upcoming Second Annual Inspiring Women in STEM Conference on December 2 at Sanofi in Bridgewater. Please click here for our full listing of events.